January 12, 2025 05:55 PM EST
Deals
Pharma

Break­ing: J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port

Kyle LaHucik

Senior Reporter

John­son & John­son is con­sid­er­ing an ac­qui­si­tion of CNS drug­mak­er In­tra-Cel­lu­lar Ther­a­pies, ac­cord­ing to anony­mous sources cit­ed in a Bloomberg News

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Post-Hoc: The em­bryo edit­ing de­bate is back

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

A service from the Financial Times